In 6786 patients with EGFR variation–positive NSCLC in the AD group, 3525 patients [51.9%], 380 patients [5.6%], 520 patients [7.7%], and 2327 patients [34.3%] were clinical stages I, II, III, and IV, respectively. Here, EGFR is linked to non-small cell lung carcinoma.